Skip to content
ATLAS PREP HQ
Growth Hormone

GHRP-2

Pralmorelin / growth hormone-releasing peptide-2, a synthetic hexapeptide

Ghrelin-receptor agonist research focused on stimulating growth-hormone secretion.

Limited Human Evidence

Route

Subcutaneous.

Common format

5 mg vial

Research focus

GH secretion

Evidence level

Limited Human Evidence

Typical cycle

8–12 weeks

Growth Hormone research motifGrowth Hormone

GHRP-2 in 30 seconds

Atlas Fast Read

What it is

Pralmorelin / growth hormone-releasing peptide-2, a synthetic hexapeptide

Why people care

Ghrelin-receptor agonist research focused on stimulating growth-hormone secretion.

Human evidence

Limited Human Evidence — Human interventional or clinical data exist, but studies are small, early-phase, mixed, indirect, route-specific, or not confirmatory.

Biggest misconception

Key gaps include larger independent trials, clearer dose-response data, long-term safety, clinically meaningful endpoints, and evidence that findings generalize beyond the narrow populations or routes already studied.

Bottom line

GHRP-2 has a real human signal or documented human pharmacology, but evidence is too small, mixed, route-specific, or indication-specific to justify broad claims.

Overview

What is GHRP-2?

GHRP-2 is pralmorelin / growth hormone-releasing peptide-2, a synthetic hexapeptide. Ghrelin-receptor agonist research focused on stimulating growth-hormone secretion.

GHRP-2 emerged from growth-hormone secretagogue research in the 1980s and 1990s. It has been used experimentally as a GH-releasing agent and has human endocrine pharmacology data.

Mechanism

How it works

Agonizes the ghrelin/growth-hormone-secretagogue receptor (GHSR-1a) in the hypothalamus and pituitary, increasing pulsatile GH secretion and indirectly IGF-1. It can also affect appetite and ACTH/cortisol to a lesser degree.

Research areas

GH secretionendocrine testingbody composition researchappetite/metabolism

Evidence

What does the evidence actually say?

Limited Human Evidence

Human interventional or clinical data exist, but studies are small, early-phase, mixed, indirect, route-specific, or not confirmatory.

01

Preclinical Evidence

02

Limited Human Evidence

03

Strong Human Evidence

Human evidence

Human endocrine studies show that GHRP-2 increases growth-hormone secretion and can affect other pituitary hormones. These studies establish pharmacologic activity, but not broad performance, anti-aging, or body-composition benefits.

Preclinical evidence

Animal work and receptor pharmacology established ghrelin-receptor-mediated GH release and appetite/endocrine effects. Human studies confirm acute endocrine activity.

Knowledge gaps

Key gaps include larger independent trials, clearer dose-response data, long-term safety, clinically meaningful endpoints, and evidence that findings generalize beyond the narrow populations or routes already studied.

Protocol

Research protocol

DoseFrequencyTimingCycle

Dose

Community reference: 100–300 mcg/day, generally titrated toward ~200 mcg/day.

Frequency

Once daily in the community protocol; older endocrine studies used different acute/repeated schedules.

Timing

Evening can align with nocturnal GH physiology; fasting around the dose is common research practice.

Route

Subcutaneous.

Cycle length

8–12 weeks

Reconstitution

Community reference: 0.5 mL bacteriostatic water per 5 mg vial = 10 mg/mL.

Storage

Community reference: lyophilized frozen; reconstituted 2–8 °C and use within about 2–3 weeks.

Monitoring

IGF-1, fasting glucose/HbA1c, edema, BP; cortisol and prolactin may be relevant because older GHRPs can affect those axes.

Protocols vary widely between sources. Investigational compounds are not approved therapies, and approved products should follow their official labeling. Nothing here is medical advice.

Safety

Safety, side effects, and precautions

Side effects

Potential GH/IGF-axis effects include edema, joint pain, tingling/carpal-tunnel-like symptoms, headache, flushing, increased appetite in some secretagogues, and worsening glucose tolerance. Injection-site reactions can occur. GHRP-2 may also raise cortisol/prolactin in some settings.

Contraindications

Avoid in active malignancy and use extreme caution with uncontrolled diabetes, proliferative retinopathy, untreated pituitary disease, pregnancy/breastfeeding or significant edema. Exact contraindications are not established for research formulations.

Interactions

GH/IGF signaling can alter glucose control, so insulin and other glucose-lowering therapy may require closer monitoring. Glucocorticoids can blunt GH effects; thyroid status can influence response. Formal interaction data are limited for research secretagogues.

Stacks

Common stacks

No well-supported stack is highlighted for this peptide yet.

Questions

FAQ

References

Sources

Atlas

The Atlas verdict

GHRP-2 has a real human signal or documented human pharmacology, but evidence is too small, mixed, route-specific, or indication-specific to justify broad claims. The most defensible use of the literature is to separate what has actually been measured in people from what is still extrapolated from mechanism or animal work.

More in Growth Hormone

Growth Hormone

CJC-1295 DAC

Long-acting GHRH analog research designed to extend growth-hormone signaling over multiple days.

Read guide

Growth Hormone

CJC-1295 NO DAC + Ipamorelin

GHRH plus growth-hormone secretagogue research intended to support more pulsatile GH release.

Read guide

Growth Hormone

GHRP-6

Ghrelin-mimetic peptide research examining growth-hormone release and ghrelin-receptor signaling.

Read guide